The PARADIGM of ARNI's: Assessing reasons for non-implementation in heart failure

Mitja Lainscak; Andrew J S Coats

doi:10.1016/j.ijcard.2016.02.130

The PARADIGM of ARNI's: Assessing reasons for non-implementation in heart failure

Int J Cardiol. 2016 Jun 1:212:187-9. doi: 10.1016/j.ijcard.2016.02.130. Epub 2016 Mar 2.

Authors

Mitja Lainscak¹, Andrew J S Coats²

Affiliations

¹ Department of Cardiology and Department of Research and Education, General Hospital Celje, Celje, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. Electronic address: [email protected].
² Monash University, Australia; University of Warwick, UK.

PMID: 27038730
DOI: 10.1016/j.ijcard.2016.02.130

Abstract

Several trials have targeted neutral endopeptidase to demonstrate benefits for patients with heart failure. In the PARADIGM-HF trial, a combination of sacubitril and valsartan was superior to enalapril in reducing the risk of death and of hospitalization for heart failure. In this editorial we apply the trial to heart failure population at large to estimate what proportion of patients might actually be treated in daily practice.

Publication types

Editorial

MeSH terms

Aminobutyrates / therapeutic use
Angiotensin Receptor Antagonists / therapeutic use*
Biphenyl Compounds
Drug Combinations
Enalapril / therapeutic use
Female
Heart Failure / drug therapy*
Heart Failure / enzymology
Humans
Male
Middle Aged
Neprilysin / antagonists & inhibitors*
Randomized Controlled Trials as Topic
Tetrazoles / therapeutic use
Treatment Outcome
Valsartan / therapeutic use

Substances

Aminobutyrates
Angiotensin Receptor Antagonists
Biphenyl Compounds
Drug Combinations
Tetrazoles
Enalapril
Valsartan
Neprilysin
sacubitril and valsartan sodium hydrate drug combination